Marco Galluzzo - Publications

Corrigendum to "Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology" [Digestive and Liver Disease 58 (2026) 1051-1060].

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: August 30, 2026

Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experience.

Journal: Expert opinion on biological therapy

Published: April 01, 2026

Toward the definition of moderate psoriasis: an expert opinion.

Journal: The Journal of dermatological treatment

Published: February 23, 2026

Effectiveness of scabies treatments in Italy (SCAB-net): a prospective observational study.

Journal: The Lancet. Infectious diseases

Published: February 09, 2026

Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study.

Journal: The Journal of dermatological treatment

Published: February 06, 2026

Efficacy and safety of mogamulizumab in Sézary syndrome with concomitant Crohn's disease.

Journal: Dermatology reports

Published: February 01, 2026

Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: January 19, 2026

Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: January 19, 2026

Genetic profiling of patients with atopic dermatitis reveals immune and skin barrier variants associated with generalized eczema and optimal response to Dupilumab therapy.

Journal: Frontiers in immunology

Published: January 15, 2026

Beneficial effects of upadacitinib on a subgroup of patients with atopic dermatitis and hidradenitis suppurativa: a multicenter, real-world retrospective study.

Journal: Frontiers in immunology

Published: December 18, 2025

Long-Term Impact of Guselkumab on Systemic Inflammation Indices in Moderate-to-Severe Psoriasis.

Journal: Journal of clinical medicine

Published: December 09, 2025

AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 Weeks.

Journal: Dermatology and therapy

Published: December 01, 2025